J&J’s $100B Revenue Runway: How Next-Gen Drugs Are Plugging the Stelara Gap

For healthcare professionals and hospital systems, J&J’s blowout quarter isn’t just a Wall Street story—it’s a real-time measure of pipeline durability. As biosimilars flood the immunology market and Stelara’s revenue slides, the performance of next-generation therapies like Rybrevant and Carvykti directly impacts treatment algorithms and formulary decisions. The earnings beat suggests that J&J’s portfolio evolution is working, with newly approved drugs filling the gap and ensuring ongoing innovation access for patients.

Johnson & Johnson delivered a standout second-quarter earnings report on July 13, 2026, sending its stock further into record territory and prompting management to raise full-year revenue and earnings guidance. The healthcare conglomerate now expects to surpass $100 billion in annual revenue for the first time in its history, underscoring the success of its strategic pivot toward higher-growth pharmaceuticals and medical devices following the 2023 spinoff of its consumer health unit, Kenvue. The stock has already rallied 22% in the first half of 2026, as investors rotated into defensively positioned, cash-generating stalwarts amid rising macroeconomic uncertainty and skepticism about the artificial intelligence boom. J&J’s results illustrate why this rotation has gathered steam: the company benefits from a durable demand profile, with patients requiring surgeries and chronic medications regardless of economic cycles, and its diversified portfolio smooths over the lumpiness that can plague pure-play biotechs.

“

As biosimilars flood the immunology market and Stelara’s revenue slides, the performance of next-generation therapies like Rybrevant and Carvykti directly impacts treatment algorithms and formulary decisions.

What made the recent quarter particularly impressive is how J&J is managing the slow-motion patent cliff surrounding its former blockbuster Stelara. The immunology drug, which treats conditions such as psoriasis and Crohn’s disease, peaked at more than $10 billion in sales in 2024, but biosimilar competition has begun to erode that revenue stream. Instead of a steep cliff, J&J has engineered a relatively smooth transition, thanks to a combination of lifecycle management, contracting strategies, and most importantly, a maturing next-generation pipeline. Oncology drugs Rybrevant (for non-small cell lung cancer) and Carvykti (a CAR-T therapy for multiple myeloma) have rapidly gained share, while immunology replacement Tremfya expanded its label into ulcerative colitis and other indications. The quarter’s blowout performance was driven in large part by these younger assets, which together are on a trajectory to more than offset Stelara’s decline within the next 12 to 18 months.

From a portfolio perspective, the post-Kenvue J&J is now essentially two businesses: pharmaceuticals and medtech. Both are benefiting from secular tailwinds. The medtech division, encompassing surgical robotics, orthopedics, and vision care, is experiencing a recovery in procedure volumes as hospitals push through backlogs and aging demographics increase demand. Within pharmaceuticals, oncology and immunology remain the star performers, but the company’s neuroscience and cardiovascular pipelines also contain potential catalysts, including late-stage assets for depression and hypertension. The earnings beat also had an operational flavor: gross margins improved slightly, reflecting manufacturing efficiencies and a favorable product mix, while R&D spending as a percentage of sales held steady, suggesting disciplined investment without jeopardizing future growth.